Literature DB >> 17449137

RNAi therapeutics: principles, prospects and challenges.

Lars Aagaard1, John J Rossi.   

Abstract

RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other antisense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression. Despite the excitement about this remarkable biological process for sequence specific gene regulation, there are a number of hurdles and concerns that must be overcome prior to making RNAi a real therapeutic modality, which include off-target effects, triggering of type I interferon responses, and effective delivery in vivo. This review discusses mechanistic aspects of RNAi, the potential problem areas and solutions and therapeutic applications. It is anticipated that RNAi will be a major therapeutic modality within the next several years, and clearly warrants intense investigation to fully understand the mechanisms involved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449137      PMCID: PMC1978219          DOI: 10.1016/j.addr.2007.03.005

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  115 in total

1.  The widespread impact of mammalian MicroRNAs on mRNA repression and evolution.

Authors:  Kyle Kai-How Farh; Andrew Grimson; Calvin Jan; Benjamin P Lewis; Wendy K Johnston; Lee P Lim; Christopher B Burge; David P Bartel
Journal:  Science       Date:  2005-11-24       Impact factor: 47.728

2.  Silencing of microRNAs in vivo with 'antagomirs'.

Authors:  Jan Krützfeldt; Nikolaus Rajewsky; Ravi Braich; Kallanthottathil G Rajeev; Thomas Tuschl; Muthiah Manoharan; Markus Stoffel
Journal:  Nature       Date:  2005-10-30       Impact factor: 49.962

3.  3' UTR seed matches, but not overall identity, are associated with RNAi off-targets.

Authors:  Amanda Birmingham; Emily M Anderson; Angela Reynolds; Diane Ilsley-Tyree; Devin Leake; Yuriy Fedorov; Scott Baskerville; Elena Maksimova; Kathryn Robinson; Jon Karpilow; William S Marshall; Anastasia Khvorova
Journal:  Nat Methods       Date:  2006-03       Impact factor: 28.547

4.  MicroRNA therapeutics: a new niche for antisense nucleic acids.

Authors:  Scott M Hammond
Journal:  Trends Mol Med       Date:  2006-02-10       Impact factor: 11.951

5.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

6.  RNA interference against Hec1 inhibits tumor growth in vivo.

Authors:  E N Gurzov; M Izquierdo
Journal:  Gene Ther       Date:  2006-01       Impact factor: 5.250

7.  Characterization of cell lines carrying self-replicating hepatitis C virus RNAs.

Authors:  T Pietschmann; V Lohmann; G Rutter; K Kurpanek; R Bartenschlager
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

8.  Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.

Authors:  N Krieger; V Lohmann; R Bartenschlager
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

9.  Efficient initiation of HCV RNA replication in cell culture.

Authors:  K J Blight; A A Kolykhalov; C M Rice
Journal:  Science       Date:  2000-12-08       Impact factor: 47.728

10.  Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging.

Authors:  Derek W Bartlett; Mark E Davis
Journal:  Nucleic Acids Res       Date:  2006-01-12       Impact factor: 16.971

View more
  253 in total

1.  Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders.

Authors:  Mohammad-Reza Noori-Daloii; Majid Mojarrad; Ali Rashidi-Nezhad; Majid Kheirollahi; Ali Shahbazi; Mehdi Khaksari; Asghar Korzebor; Ali Goodarzi; Maryam Ebrahimi; Ali Reza Noori-Daloii
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

2.  Targeted gene silencing using RGD-labeled chitosan nanoparticles.

Authors:  Hee Dong Han; Lingegowda S Mangala; Jeong Won Lee; Mian M K Shahzad; Hye Sun Kim; Deyu Shen; Eun Ji Nam; Edna M Mora; Rebecca L Stone; Chunhua Lu; Sun Joo Lee; Ju Won Roh; Alpa M Nick; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Clin Cancer Res       Date:  2010-06-10       Impact factor: 12.531

3.  MicroRNA signatures of stem cells.

Authors:  Dipak K Das; Partha Mukhopadhyay
Journal:  Exp Clin Cardiol       Date:  2011

4.  Nanoparticle based galectin-1 gene silencing, implications in methamphetamine regulation of HIV-1 infection in monocyte derived macrophages.

Authors:  Jessica L Reynolds; Wing Cheung Law; Supriya D Mahajan; Ravikumar Aalinkeel; Bindukumar Nair; Donald E Sykes; Ken-Tye Yong; Rui Hui; Paras N Prasad; Stanley A Schwartz
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-12       Impact factor: 4.147

Review 5.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

6.  Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy.

Authors:  Che-Kai Tsao; William K Oh
Journal:  Asian J Androl       Date:  2010-11-15       Impact factor: 3.285

7.  Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers.

Authors:  Carlee E Ashley; Eric C Carnes; Katharine E Epler; David P Padilla; Genevieve K Phillips; Robert E Castillo; Dan C Wilkinson; Brian S Wilkinson; Cameron A Burgard; Robin M Kalinich; Jason L Townson; Bryce Chackerian; Cheryl L Willman; David S Peabody; Walker Wharton; C Jeffrey Brinker
Journal:  ACS Nano       Date:  2012-02-14       Impact factor: 15.881

8.  Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation.

Authors:  Hironobu Takahashi; Yuwei Wang; David W Grainger
Journal:  J Control Release       Date:  2010-08-19       Impact factor: 9.776

9.  Comparative analysis of RNAi screening technologies at genome-scale reveals an inherent processing inefficiency of the plasmid-based shRNA hairpin.

Authors:  Bhavneet Bhinder; David Shum; Hakim Djaballah
Journal:  Comb Chem High Throughput Screen       Date:  2014-02       Impact factor: 1.339

Review 10.  Update on current and potential nanoparticle cancer therapies.

Authors:  Jonathan S Rink; Michael P Plebanek; Sushant Tripathy; C Shad Thaxton
Journal:  Curr Opin Oncol       Date:  2013-11       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.